Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 487.32 Billion KRW | 6.66% |
| 2022 | 456.89 Billion KRW | 7.13% |
| 2021 | 426.48 Billion KRW | 4.11% |
| 2020 | 409.66 Billion KRW | 2.01% |
| 2019 | 401.58 Billion KRW | -0.33% |
| 2018 | 402.9 Billion KRW | -2.62% |
| 2017 | 413.72 Billion KRW | -15.91% |
| 2016 | 491.98 Billion KRW | 10.52% |
| 2015 | 445.16 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 487.15 Billion KRW | -0.04% |
| 2024 Q2 | 493.46 Billion KRW | 1.29% |
| 2023 Q1 | 483.26 Billion KRW | 5.77% |
| 2023 FY | 487.32 Billion KRW | 6.66% |
| 2023 Q4 | 487.32 Billion KRW | -3.37% |
| 2023 Q3 | 504.29 Billion KRW | 3.14% |
| 2023 Q2 | 488.92 Billion KRW | 1.17% |
| 2022 FY | 456.89 Billion KRW | 7.13% |
| 2022 Q2 | 430.8 Billion KRW | 1.02% |
| 2022 Q1 | 426.45 Billion KRW | -0.01% |
| 2022 Q4 | 456.89 Billion KRW | 4.68% |
| 2022 Q3 | 436.46 Billion KRW | 1.31% |
| 2021 FY | 426.48 Billion KRW | 4.11% |
| 2021 Q2 | 441.54 Billion KRW | 0.1% |
| 2021 Q1 | 441.11 Billion KRW | 7.68% |
| 2021 Q3 | 441.75 Billion KRW | 0.05% |
| 2021 Q4 | 426.48 Billion KRW | -3.46% |
| 2020 FY | 409.66 Billion KRW | 2.01% |
| 2020 Q1 | 410.44 Billion KRW | 2.21% |
| 2020 Q4 | 409.66 Billion KRW | -2.02% |
| 2020 Q3 | 418.09 Billion KRW | 0.0% |
| 2020 Q2 | 418.09 Billion KRW | 1.86% |
| 2019 Q1 | 414.64 Billion KRW | 2.91% |
| 2019 Q4 | 401.58 Billion KRW | -0.0% |
| 2019 FY | 401.58 Billion KRW | -0.33% |
| 2019 Q3 | 401.58 Billion KRW | -3.31% |
| 2019 Q2 | 415.35 Billion KRW | 0.17% |
| 2018 FY | 402.9 Billion KRW | -2.62% |
| 2018 Q4 | 402.9 Billion KRW | -3.25% |
| 2018 Q3 | 416.42 Billion KRW | -0.52% |
| 2018 Q2 | 418.59 Billion KRW | 2.84% |
| 2018 Q1 | 407.02 Billion KRW | -1.62% |
| 2017 Q3 | 418.05 Billion KRW | 4.2% |
| 2017 Q4 | 413.72 Billion KRW | -1.03% |
| 2017 FY | 413.72 Billion KRW | -15.91% |
| 2017 Q2 | 401.19 Billion KRW | 0.0% |
| 2016 FY | 491.98 Billion KRW | 10.52% |
| 2015 FY | 445.16 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -145.859% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 75.1% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 44.433% |
| HANDOK Inc. | 790.33 Billion KRW | 38.34% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -185.621% |
| Yuhan Corporation | 2814.07 Billion KRW | 82.683% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 62.947% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -421.322% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 75.035% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -103.267% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -3.929% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -323.86% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -106.015% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -39.881% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -145.859% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -16.254% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 2.491% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 17.318% |
| JW Holdings Corporation | 1176.26 Billion KRW | 58.57% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 20.275% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 65.251% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 24.45% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -39.203% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -216.361% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -31.468% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -145.859% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 54.796% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 72.472% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 24.45% |
| Yuhan Corporation | 2814.07 Billion KRW | 82.683% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 44.622% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -115.059% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 50.96% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 24.45% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -16.057% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -3.938% |
| CKD Bio Corp. | 293.78 Billion KRW | -65.879% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 4.069% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 13.743% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -21.459% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -39.203% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 66.53% |
| Boryung Corporation | 922.36 Billion KRW | 47.165% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -10.14% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -3.929% |
| JW Lifescience Corporation | 255.83 Billion KRW | -90.484% |